The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [(14)C]-BI 425809 in Healthy Males

BACKGROUND AND OBJECTIVES: BI 425809, a novel glycine transporter-1 inhibitor, may ameliorate cognitive deficits in schizophrenia. The objectives of the studies were: to assess absolute bioavailability of oral BI 425809 compared with intravenous (IV) microtracer infusion (study 1), and to determine...

Descripción completa

Detalles Bibliográficos
Autores principales: Burkard, Ute, Desch, Michael, Shatillo, Yury, Wunderlich, Glen, Mack, Salome Rebecca, Schlecker, Christina, Teitelbaum, Aaron M., Liu, Pingrong, Chan, Tom S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901509/
https://www.ncbi.nlm.nih.gov/pubmed/34936055
http://dx.doi.org/10.1007/s40261-021-01111-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901509/
https://www.ncbi.nlm.nih.gov/pubmed/34936055
http://dx.doi.org/10.1007/s40261-021-01111-9

Ejemplares similares